-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-14927 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFP-14927 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFP-14927 in Solid Tumor Drug Details: DFP-14927 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-90011 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-90011 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BMS-90011 in Solid Tumor Drug Details: BMS-90011 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radgocitabine in Refractory Acute Myeloid Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radgocitabine in Refractory Acute Myeloid Leukemia Drug Details: Radgocitabine (DFP-10917) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFP-11207 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DFP-11207 in Gastric Cancer Drug Details:DFP-11207 is under development for the treatment of solid tumors including...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TS-23 in Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TS-23 in Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TS-23 in Ischemic Stroke Drug Details: DS-9231 (TS23) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MIC-Lx in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MIC-Lx in Kidney Transplant Rejection report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radgocitabine in Relapsed Acute Myeloid Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radgocitabine in Relapsed Acute Myeloid Leukemia Drug Details: Radgocitabine (DFP-10917) is under development for...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...